首页> 外文期刊>Journal of Immunological Methods >Construction of recombinant extended single-chain antibody peptide conjugates for use in the diagnosis of HIV-1 and HIV-2.
【24h】

Construction of recombinant extended single-chain antibody peptide conjugates for use in the diagnosis of HIV-1 and HIV-2.

机译:构建用于诊断HIV-1和HIV-2的重组扩展单链抗体肽结合物。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The construction, expression and evaluation of recombinant scFv based HIV diagnostic reagents are described. In a whole-blood, erythrocyte agglutination assay format, recombinant scFv antibodies (expressed in Escherichia coli), linked to a spacer domain and HIV-gp36 or -gp41 peptides, were shown to be able to detect efficiently natural antibodies against HIV in human serum. Performance in trials suggests that these single chain reagents have potential as alternatives to existing Fab-peptide chemical conjugates. We also report the construction of an inducible expression vector, pGC, which can be used both in laboratory experiments and in large-scale fed-batch fermentations. It was found that while the base scFv reagent (lacking a spacer) functioned as well as the Fab peptide conjugate in assays where whole (negative) blood was spiked with mouse monoclonal anti-HIV antibodies (IgG or IgM), clinical assays using human sera showed lower sensitivities and increased false negatives. This deficiency was overcome by inclusion of the natural 1C3 kappa (light) chain domain as a spacer arm between the scFv and HIV peptide tags. This spacer was thought to overcome steric constraints which would otherwise prevent efficient interaction between the reagent (once bound to the surface of red blood cells) and the various serum antibodies against the respective C-terminal peptide epitopes. As a result of this important modification, performance of the extended scFv reagent (for both HIV-1 and HIV-2) equalled that of the current commercial technology in limited trials.
机译:描述了基于重组scFv的HIV诊断试剂的构建,表达和评估。在全血凝集测定法中,重组scFv抗体(在大肠杆菌中表达)与间隔域和HIV-gp36或-gp41肽连接,能够有效检测人血清中针对HIV的天然抗体。试验性能表明,这些单链试剂具有替代现有Fab-肽化学偶联物的潜力。我们还报告了可诱导表达载体pGC的构建,该载体可用于实验室实验和大规模分批补料发酵。发现在用小鼠单克隆抗HIV抗体(IgG或IgM)加标全血(阴性)的测定中,虽然基本scFv试剂(无间隔子)的功能与Fab肽结合物相同,但使用人血清的临床测定显示较低的敏感度并增加假阴性。通过在scFv和HIV肽标签之间加入天然1C3κ(轻)链结构域作为间隔臂,克服了这一缺陷。人们认为该间隔物克服了空间限制,否则将阻止试剂(一旦结合到红细胞表面)和针对各自C-末端肽表位的各种血清抗体之间的有效相互作用。由于这项重要的修改,扩展的scFv试剂(针对HIV-1和HIV-2)的性能在有限的试验中与目前的商业技术相当。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号